Table 2.
Therapy data
| Surgery and concomitant therapy | ||
|---|---|---|
| n | % | |
| Patients with incomplete (primary) surgery | 4 | 10.3 |
| Patients with surgical nodal staging | 11 | 28.2 |
| Clinical nodal staging | 28 | 71.8 |
| Complete chemotherapy (Cisplatin 40 mg/m2 weekly) | 31 | 79.5 |
| Patients without all cycles of chemotherapy due to hematological toxicities | 3 | 7.7 |
| Patients without chemotherapy due to contraindication or refusal | 5 | 12.8 |
| Radiotherapy dosage | ||
| Median (Gy) | Range (Gy) | |
| Radiotherapy duration (days) | 60 | 46 - 96 |
| EBRT elective pelvic nodal dose (Gy) | 50.4 | 45-55.8 |
| EBRT elective paraaortral dose (Gy) | 47.7 | 45 - 50.4 |
| EBRT Tumor Boost dose (Gy) | 9 | 5.4 - 21.6 |
| EBRT Total Tumor Dose (Gy) | 59.4 | 50.4 - 72 |
| LN Boost dose (Gy) | 62 | 59.4 - 64.8 |
| Brachytherapy total dose (Gy) | 18 | 10 - 24 |
| Brachytherapy single dose (Gy) | 6 | 5-6 |